John TsoJohnTso

A multinational industrial manufacturer in connection with an anti-corruption focused due diligence review of a significant acquisition and supporting integration of the acquired entity into the client’s anti-corruption compliance program and related internal controls.

A multinational bank in connection with the development of its anti-bribery and anti-corruption policy.

A multi-listed technology company in connection with a comprehensive risk assessment concerning its operations in China.

A multinational medical device company in connection with a compliance health check and transaction testing concerning its operations in China.

A European luxury goods company in connection with the development of its anti-bribery and corruption guidelines and economic sanctions policy for Asia markets.

Multiple investment funds in connection with the development of their internal controls and codes of business conduct.

A Hong Kong charity in connection with the development of its anti-money laundering policy.

Hong Kong IPO issuers and sponsors in connection with sanctions and trade controls matters.

Acted as the chief compliance officer of an S. funded real estate company in China.

A Hong Kong-listed Chinese life sciences company in an HKIAC arbitration seated in Hong Kong against a financial services company.

A Hong Kong-listed Chinese technology company in an HKIAC arbitration seated in Hong Kong against an investment management firm.

An S. private equity real estate fund in parallel HKIAC and CIETAC arbitrations arising out of a PRC-foreign real estate joint venture dispute in excess of $200 million.

A Chinese private equity fund in an HKIAC arbitration seated in Hong Kong arising out of its acquisition of a leading software company in China from a U.S.-listed conglomerate.

A leading Chinese media company in an HKIAC arbitration seated in Hong Kong against a European licensor of one of the most popular television programs in the world.

An entrepreneur and related privately held company in an HKIAC arbitration seated in Hong Kong against institutional investors regarding an educational services venture in China.

A Chinese technology company in a U.S. litigation in connection with the legality of its biometrics technology.

A leading multinational pharmaceutical company in a dispute arising out of the licensing and distribution arrangements in China involving one of its major products.

A global conglomerate in a dispute arising out of its investment in Chinese-foreign chemical production joint ventures.